LeMaitre Vascular Company Profile (NASDAQ:LMAT)

LeMaitre Vascular trades on the NASDAQ under the ticker symbol "LMAT."

LeMaitre Vascular declared a quarterly dividend on Friday, July 28th. Shareholders of record on Wednesday, August 23rd will be given a dividend of $0.055 per share on Thursday, September 7th. This represents a $0.22 dividend on an annualized basis and a yield of 0.59%. The ex-dividend date is Monday, August 21st. View LeMaitre Vascular's Dividend History.

LeMaitre Vascular declared that its Board of Directors has initiated a share repurchase program on Friday, July 28th 2017, which permits the company to repurchase $7,500,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 1.4% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its shares are undervalued.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced its quarterly earnings results on Thursday, July, 27th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. The firm had revenue of $25.80 million for the quarter, compared to analysts' expectations of $25.42 million. LeMaitre Vascular had a net margin of 14.19% and a return on equity of 15.02%. The business's quarterly revenue was up 15.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.14 earnings per share. View LeMaitre Vascular's Earnings History.

LeMaitre Vascular is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for LeMaitre Vascular.

LeMaitre Vascular issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $0.79 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.70. The company issued revenue guidance of $101.9 million, compared to the consensus revenue estimate of $100.61 million.LeMaitre Vascular also updated its Q3 guidance to $0.20 EPS.

6 equities research analysts have issued 1-year target prices for LeMaitre Vascular's stock. Their predictions range from $28.00 to $32.00. On average, they anticipate LeMaitre Vascular's stock price to reach $30.00 in the next twelve months. View Analyst Ratings for LeMaitre Vascular.

Here are some recent quotes from research analysts about LeMaitre Vascular stock:

• 1. According to Zacks Investment Research, "LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time. " (8/1/2017)
• 2. Canaccord Genuity analysts commented, "We view this event as largely priced in, given the previous success in narcolepsy in a Phase II trial and a successful read-out from two Phase III trials in excessive sleepiness (ES) associated with obstructive sleep apnea (OSA). We currently model an 80% probability of approval and risk-adjusted sales of $558.9 million in 2026." (4/27/2017)

Some companies that are related to LeMaitre Vascular include Accelerate Diagnostics (AXDX), Mazor Robotics (MZOR), Natus Medical Incorporated (BABY), ABAXIS (ABAX), Luminex Corporation (LMNX), Pacific Biosciences of California (PACB), GenMark Diagnostics (GNMK), Accuray Incorporated (ARAY), ViewRay (VRAY), Corindus Vascular Robotics (CVRS), Cogentix Medical (CGNT), Cytosorbents Corporation (CTSO), Neovasc (NVCN), Harvard Bioscience (HBIO), Viveve Medical (VIVE), IRIDEX Corporation (IRIX), EDAP TMS S.A. (EDAP) and FULGENT GENETIC (FLGT).

LeMaitre Vascular's management team includes the folowing people:

• George W. LeMaitre, Chairman of the Board, Chief Executive Officer
• David B. Roberts, President, Director
• Joseph P. Pellegrino Jr., Chief Financial Officer, Director
• Peter R. Gebauer, President - International Operations
• Trent G. Kamke, Senior Vice President - Operations
• Cornelia W. LeMaitre, Vice President - Human Resources
• Lawrence J. Jasinski, Independent Director
• John J. O'Connor, Independent Director
• John A. Roush, Independent Director
• Michael H. Thomas, Independent Director

LeMaitre Vascular's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (5.15%), Vanguard Group Inc. (4.33%), AWM Investment Company Inc. (3.49%), Conestoga Capital Advisors LLC (3.00%), State Street Corp (2.01%) and Thomson Horstmann & Bryant Inc. (1.95%). Company insiders that own LeMaitre Vascular stock include Cornelia W Lemaitre, David B Roberts, George W Lemaitre, Joseph P Pellegrino, Jr, Lawrence J Jasinski, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Institutional Ownership Trends for LeMaitre Vascular.

LeMaitre Vascular's stock was sold by a variety of institutional investors in the last quarter, including AWM Investment Company Inc., William Blair Investment Management LLC, Cornerstone Capital Management Holdings LLC., Ameriprise Financial Inc., Rice Hall James & Associates LLC, Grandeur Peak Global Advisors LLC, Perkins Capital Management Inc. and Wells Fargo & Company MN. Company insiders that have sold LeMaitre Vascular stock in the last year include David B Roberts, George W Lemaitre, Lawrence J Jasinski, Michael T Wijas, Peter R Gebauer and Trent G Kamke. View Insider Buying and Selling for LeMaitre Vascular.

LeMaitre Vascular's stock was acquired by a variety of institutional investors in the last quarter, including Conestoga Capital Advisors LLC, Vanguard Group Inc., Janus Henderson Group PLC, Bank of New York Mellon Corp, Principal Financial Group Inc., Fiera Capital Corp, State Street Corp and Nationwide Fund Advisors. View Insider Buying and Selling for LeMaitre Vascular.

Shares of LeMaitre Vascular can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of LeMaitre Vascular stock can currently be purchased for approximately $37.25.